Matrixyl vs Oligopeptide-1
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Palmitoyl Pentapeptide-4, Pal-KTTKS
Matrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.
Also: sh-Oligopeptide-1, rh-Oligopeptide-1
sh-Oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (EGF), a 53-amino-acid protein your skin uses to tell cells to divide and repair. It shows up in 'EGF serums' aimed at wrinkles, texture and post-procedure recovery. It is a cosmetic ingredient in skincare, not an FDA-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- Oligopeptide-1 has stronger research evidence (Human Trials) compared to Matrixyl (Limited Research).
Detailed Comparison
| Attribute | Matrixyl | Oligopeptide-1 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | KTTKS is a five-amino-acid piece of type I collagen. When collagen breaks down, fragments like this are released, and the skin reads them as a signal that the matrix needs repair, which prompts fibroblasts to make more collagen and other support proteins, a process called matrikine signaling. Matrixyl essentially feeds the skin that repair signal on purpose. The palmitoyl (fatty acid) tail is bolted on to make the otherwise water-loving peptide lipophilic enough to penetrate the outer skin layer, which is the part that actually lets a topical work. | EGF binds the EGF receptor on keratinocytes and fibroblasts and switches on growth and repair signaling: cell division, migration, and production of matrix proteins. That is why it has been studied for wound healing, and why cosmetic brands use it to support skin renewal. Two practical problems: EGF is a fairly large protein, so getting it through intact skin is hard (which is why many studies pair it with microneedling or lasers), and it is fragile, so how much stays active in a jar at room temperature is a fair question. The same growth-promoting signal is also the source of the safety debate: EGF receptor signaling drives several cancers, so the concern is not that EGF causes cancer, but whether it could encourage abnormal cells that are already there. |
| Common Dosing | Limited community data available See research protocols | Low parts-per-million concentration in a serum Once or twice daily |
| Administration | Topical (serums, creams) | Topical (serums, ampoules, creams); sometimes combined with microneedling in clinic |
| Typical Duration | 8-12 weeks for visible results, ongoing use | Studies typically ran 4 to 12 weeks |
| Best Time to Take | Morning or as directed | Evening skincare routine, or right after an in-clinic procedure |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Matrixyl has the kind of human data most cosmetic peptides lack. The pivotal Robinson 2005 study in the International Journal of Cosmetic Science was a 12-week, double-blind, placebo-controlled, split-face trial in 93 women aged 35 to 55, comparing a moisturizer with 3 ppm Pal-KTTKS against the same moisturizer alone, and it found significant reductions in wrinkles and fine lines on the peptide side, with good tolerability. Cell and lab studies support the mechanism, showing increased synthesis of collagen I and IV and fibronectin. The frequently quoted figures like 117 percent collagen increase or 68 percent wrinkle reduction come largely from manufacturer in vitro and formulation data, so treat the exact percentages skeptically even though the direction of effect is real. Overall this is a well-tolerated peptide with genuine, if modest, controlled human evidence for texture and fine lines, and it does not require injection. It will not erase deep dynamic wrinkles the way muscle-targeting treatments aim to. | A 2021 systematic review in the Journal of Cutaneous and Aesthetic Surgery (Miller-Kobisher and colleagues) found 49 articles on rhEGF for skin, including 23 aesthetic studies. Most reported less wrinkling, better hydration and elasticity, and the strongest data were for pigmentation after lasers and melasma. But the authors admit many trials were uncontrolled or not randomized, samples were often 8 to 40 people, and they called for proper controlled trials. Adverse effects were mild and short-lived. The review did not address cancer risk at all, which is a real gap. Several of the better-known growth-factor trials tested multi-factor mixtures, not EGF alone. On safety: there is no human evidence that cosmetic EGF causes skin cancer, and in vitro tests of growth-factor cosmetics on melanoma cells were reassuring, but long-term studies in healthy skin do not exist. Sensible caution: people with a history of skin cancer, many atypical moles, or active psoriasis should talk to a dermatologist before using it. Bottom line: plausible and widely used, modest and mostly low-quality efficacy data, and an unresolved theoretical safety question. |
Frequently Asked Questions: Matrixyl vs Oligopeptide-1
What is the difference between Matrixyl and Oligopeptide-1?
Matrixyl is a skin & hair peptide that matrixyl is the trade name (sederma) for palmitoyl pentapeptide-4, also written pal-kttks, a collagen-fragment peptide attached to a fatty acid so it can cross skin. unlike botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. it is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof. Oligopeptide-1 is a skin & hair peptide that sh-oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (egf), a 53-amino-acid protein your skin uses to tell cells to divide and repair. it shows up in 'egf serums' aimed at wrinkles, texture and post-procedure recovery. it is a cosmetic ingredient in skincare, not an fda-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Matrixyl or Oligopeptide-1?
Neither is universally "better" - the choice depends on your specific goals. Matrixyl is typically used for skin & hair purposes, while Oligopeptide-1 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Matrixyl and Oligopeptide-1 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Matrixyl and Oligopeptide-1 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.